What is the long-term efficacy and safety profile of CRISPR-based gene therapy for sickle cell disease beyond 2 years?
Origin: "FDA approval of Casgevy prompted long-term monitoring query"
5,623
892
Weekly
2026-04-20
Epistemic Status: Evolving
Was one status, shifting. New evidence changing the picture.
Revenue & Distribution
Revenue Generated
$89,000
Distributed to Contributors
$35,600
40% distributed · Tracked via Proven.dev provenance chain
Current Findings
Key Papers (2)
Exagamglogene Autotemcel for Sickle Cell Disease (CLIMB-SCD-121)
NEJM · 2024 · Cited in evidence chain
Long-Term Follow-Up of CRISPR Gene Therapy: 2-Year Outcomes
Blood · 2026 · Cited in evidence chain
Candidate Questions from Blast Radius
Do anti-Cas9 antibodies reduce therapy durability beyond 3 years?
InvestigateCan reduced-intensity conditioning replace busulfan for CRISPR SCD therapy?
InvestigateA question rejected today is not a bad question. It might be a premature question. Like continental drift. Like H. pylori. The system remembers what it was curious about.
Oracle Schedule
Epistemic Status Scale
Related Living Queries
Help Answer This Question
Your data, expertise, or funding can help move this query from Evolving to the next level.
View Campaign →What is the long-term efficacy and safety profile of CRISPR-based gene therapy for sickle cell disease beyond 2 years?
Origin: "FDA approval of Casgevy prompted long-term monitoring query"
5,623
892
Weekly
2026-04-20
Epistemic Status: Evolving
Was one status, shifting. New evidence changing the picture.
Revenue & Distribution
Revenue Generated
$89,000
Distributed to Contributors
$35,600
40% distributed · Tracked via Proven.dev provenance chain
Current Findings
Key Papers (2)
Exagamglogene Autotemcel for Sickle Cell Disease (CLIMB-SCD-121)
NEJM · 2024 · Cited in evidence chain
Long-Term Follow-Up of CRISPR Gene Therapy: 2-Year Outcomes
Blood · 2026 · Cited in evidence chain
Candidate Questions from Blast Radius
Do anti-Cas9 antibodies reduce therapy durability beyond 3 years?
InvestigateCan reduced-intensity conditioning replace busulfan for CRISPR SCD therapy?
InvestigateA question rejected today is not a bad question. It might be a premature question. Like continental drift. Like H. pylori. The system remembers what it was curious about.
Oracle Schedule
Epistemic Status Scale
Related Living Queries
Help Answer This Question
Your data, expertise, or funding can help move this query from Evolving to the next level.
View Campaign →